PE20120028A1 - Nueva composicion a base de acido gamma-hidroxibutirico - Google Patents
Nueva composicion a base de acido gamma-hidroxibutiricoInfo
- Publication number
- PE20120028A1 PE20120028A1 PE2011001031A PE2011001031A PE20120028A1 PE 20120028 A1 PE20120028 A1 PE 20120028A1 PE 2011001031 A PE2011001031 A PE 2011001031A PE 2011001031 A PE2011001031 A PE 2011001031A PE 20120028 A1 PE20120028 A1 PE 20120028A1
- Authority
- PE
- Peru
- Prior art keywords
- gamma
- gum
- butyric acid
- weight
- granulate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- -1 GAMMA HYDROXY-BUTYRIC ACID POLYOLS Chemical class 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 239000002702 enteric coating Substances 0.000 abstract 2
- 238000009505 enteric coating Methods 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 239000004922 lacquer Substances 0.000 abstract 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 208000009132 Catalepsy Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 206010047853 Waxy flexibility Diseases 0.000 abstract 1
- 235000010489 acacia gum Nutrition 0.000 abstract 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 abstract 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 abstract 1
- 239000000845 maltitol Substances 0.000 abstract 1
- 235000010449 maltitol Nutrition 0.000 abstract 1
- 229940035436 maltitol Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 abstract 1
- 229910000027 potassium carbonate Inorganic materials 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (A) UN GRANULADO EN EL QUE EL ACIDO GAMMA HIDROXI-BUTIRICO SE ENCUENTRA EN 35% PESO QUE COMPRENDE UN RECUBRIMIENTO ENTERICO (B) UN NUCLEO SOLIDO QUE SOPORTA AL ACIDO GAMMA HIDROXI-BUTIRICO ELEGIDO ENTRE POLIOLES TALES COMO MANITOL, SORBITOL, MALTITOL, LACTOSA; CARBONATOS TALES COMO CARBONATO DE CALCIO, POTASIO, MAGNESIO O SODIO QUE REPRESENTA EL 20-80% EN PESO DEL TOTAL DEL GRANULADO; (C) UN AGLUTINANTE ELEGIDO ENTRE ALMIDON, SACAROSA, GOMA ARABICA, POLIVINILPIRROLIDONA, ENTRE OTROS; (D) UN AGENTE DE RECUBRIMINETO ENTERICO CONSTITUIDO POR POLIMEROS METACRILICOS, GOMA LACA O HPMCM, Y/O RECUBRIMIENTO DE LIBERACION MODIFICADA CONTITUIDO POR COPOLIMEROS DE METACRILATOS Y ACRILATOS, GOMA LACA Y DERIVADOS DE CELULOSA; (E) UN LUBRICANTE Y/O AROMATIZANTE Y/O EDULCORANTE Y/O COLORANTE. DICHA COMPOSICION TIENE COMO VENTAJA AUMENTAR LA SEMIVIDA APARENTE Y LA BIODISPONIBILIDAD DEL PRINCIPIO ACTIVO SIENDO UTIL EN EL TRATAMIENTO DE CATALEPSIA EN LOS PACIENTE NARCOLEPTICOS O EN EL SINDROME DE ABSTINENCIA DEL ACOHOLISMO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0857763A FR2938431B1 (fr) | 2008-11-14 | 2008-11-14 | Nouvelle composition a base d'acide gamma-hydroxybutyrique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120028A1 true PE20120028A1 (es) | 2012-02-25 |
Family
ID=40674006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001031A PE20120028A1 (es) | 2008-11-14 | 2009-11-10 | Nueva composicion a base de acido gamma-hidroxibutirico |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8529954B2 (es) |
| EP (1) | EP2349217B1 (es) |
| JP (1) | JP2012508784A (es) |
| KR (1) | KR101563390B1 (es) |
| CN (2) | CN104688691A (es) |
| AR (1) | AR074351A1 (es) |
| AU (1) | AU2009315441B2 (es) |
| BR (1) | BRPI0916021B8 (es) |
| CA (1) | CA2743767C (es) |
| CL (1) | CL2011001114A1 (es) |
| CO (1) | CO6382106A2 (es) |
| CU (1) | CU20110109A7 (es) |
| CY (1) | CY1122209T1 (es) |
| DK (1) | DK2349217T3 (es) |
| EA (1) | EA023305B1 (es) |
| ES (1) | ES2749803T3 (es) |
| FR (1) | FR2938431B1 (es) |
| HR (1) | HRP20191911T1 (es) |
| HU (1) | HUE046321T2 (es) |
| IL (1) | IL212847A (es) |
| LT (1) | LT2349217T (es) |
| MA (1) | MA32790B1 (es) |
| MX (1) | MX2011005073A (es) |
| NZ (1) | NZ592850A (es) |
| PE (1) | PE20120028A1 (es) |
| PL (1) | PL2349217T3 (es) |
| PT (1) | PT2349217T (es) |
| SI (1) | SI2349217T1 (es) |
| SM (1) | SMT201900721T1 (es) |
| TN (1) | TN2011000231A1 (es) |
| TW (1) | TWI446906B (es) |
| UA (1) | UA103057C2 (es) |
| WO (1) | WO2010055260A1 (es) |
| ZA (1) | ZA201103542B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
| FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| FR2971422B1 (fr) * | 2011-02-11 | 2016-05-20 | Debregeas Et Associes Pharma | Granules d'acide gamma-hydroxybutyrique |
| US9050302B2 (en) * | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11000498B2 (en) | 2016-07-22 | 2021-05-11 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| BR112020012417A2 (pt) * | 2017-12-20 | 2020-11-24 | Flamel Ireland Limited | formulações embaladas de gama-hidroxibutirato de liberação modificada tendo estabilidade melhorada |
| JP7472116B2 (ja) | 2018-11-19 | 2024-04-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 耐アルコール性製剤 |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| EP4077262B1 (en) | 2019-12-20 | 2024-07-24 | XWPharma Ltd. | Methods of synthesizing 4-valyloxybutyric acid |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| AU2021292406B2 (en) | 2020-06-18 | 2024-03-14 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
| EP4167966A1 (en) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
| CN116261451A (zh) | 2020-07-24 | 2023-06-13 | 凯瑞康宁生物工程有限公司 | γ-羟基丁酸衍生物的药物组合物和药物动力学 |
| US11395801B2 (en) * | 2020-10-05 | 2022-07-26 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
| CN112868909A (zh) * | 2021-01-22 | 2021-06-01 | 湖北神舟化工有限公司 | 一种无臭型丁酸钠及其生产方法 |
| US11510892B2 (en) | 2021-03-19 | 2022-11-29 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative |
| CN117157060A (zh) * | 2021-04-16 | 2023-12-01 | 南京纽邦生物科技有限公司 | 包衣β-羟基丁酸晶体及其制备方法 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| KR20250148613A (ko) | 2023-02-03 | 2025-10-14 | 트리스 파마 인코포레이티드 | 저 나트륨 옥시베이트 밤마다 1회 투여 조성물 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4101650A (en) | 1977-04-06 | 1978-07-18 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pepstatin floating minicapsules |
| US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| IT1217783B (it) * | 1988-06-03 | 1990-03-30 | Farmaceutico Ct S R L Lab | Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative |
| IT1248588B (it) * | 1991-06-28 | 1995-01-19 | Gaetano Crepaldi | Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari. |
| IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US6214386B1 (en) | 1995-11-22 | 2001-04-10 | Recordati, S.A. | Prompt-release oral pharmaceutical compositions for extemporaneous suspensions |
| US5846971A (en) | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| JP3447042B2 (ja) * | 1997-07-23 | 2003-09-16 | フロイント産業株式会社 | 単一物質球形粒の製造方法 |
| GB9725219D0 (en) | 1997-11-29 | 1998-01-28 | Cleansharp Ltd | Tablets |
| US6350470B1 (en) | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| DK1140061T3 (da) * | 1998-12-23 | 2003-08-25 | Orphan Medical Inc | Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi |
| FR2790668B1 (fr) * | 1999-03-12 | 2002-07-26 | D B F | Granules contenant une substance vegetale et leur procede de preparation |
| MXPA01011800A (es) * | 1999-05-17 | 2003-08-19 | D B F | Granulos que contienen una sustancia vegetal y procedimiento para prepararlos. |
| FR2797185B1 (fr) | 1999-08-06 | 2001-10-26 | Galenix Dev | Composition pharmaceutique flottante comprenant une phase active et une phase non active |
| FR2823668B1 (fr) | 2001-04-20 | 2004-02-27 | Ethypharm Lab Prod Ethiques | Comprimes effervescents orodispersibles |
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| AU2002319774B2 (en) | 2001-08-06 | 2005-04-21 | Euro-Celtique S.A. | Compositions and methods to prevent abuse of opioids |
| US20030059397A1 (en) | 2001-09-17 | 2003-03-27 | Lyn Hughes | Dosage forms |
| FR2829932B1 (fr) | 2001-09-21 | 2006-11-24 | Ellipse Pharmaceuticals | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu |
| FR2829933B3 (fr) | 2001-09-21 | 2004-03-12 | Ellipse Pharmaceuticals | Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu |
| WO2004026283A1 (en) * | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sequestering subunit and related compositions and metohds |
| TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| CN1964704A (zh) | 2004-03-03 | 2007-05-16 | 特瓦制药工业有限公司 | 包含酸不稳定药物的稳定药用组合物 |
| TW200533391A (en) | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| US8193211B2 (en) * | 2004-09-30 | 2012-06-05 | Supernus Pharmaceuticals, Inc. | Controlled release compositions of gamma-hydroxybutyrate |
| US7884136B2 (en) | 2005-06-27 | 2011-02-08 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
| US20070092565A1 (en) | 2005-10-25 | 2007-04-26 | Pharmascience Inc. | Gastric retention drug delivery system |
| EP2223702B1 (en) * | 2007-12-03 | 2019-05-08 | Tomita Pharmaceutical Co., Ltd. | Core particle for pharmaceutical preparation |
| FR2949062B1 (fr) | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
| FR2949061B1 (fr) | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
-
2008
- 2008-11-14 FR FR0857763A patent/FR2938431B1/fr not_active Expired - Fee Related
-
2009
- 2009-11-10 KR KR1020117013587A patent/KR101563390B1/ko active Active
- 2009-11-10 HR HRP20191911TT patent/HRP20191911T1/hr unknown
- 2009-11-10 AU AU2009315441A patent/AU2009315441B2/en not_active Ceased
- 2009-11-10 MX MX2011005073A patent/MX2011005073A/es active IP Right Grant
- 2009-11-10 EP EP09768176.1A patent/EP2349217B1/fr active Active
- 2009-11-10 BR BRPI0916021A patent/BRPI0916021B8/pt not_active IP Right Cessation
- 2009-11-10 PT PT97681761T patent/PT2349217T/pt unknown
- 2009-11-10 LT LT09768176T patent/LT2349217T/lt unknown
- 2009-11-10 CN CN201510047649.3A patent/CN104688691A/zh active Pending
- 2009-11-10 PE PE2011001031A patent/PE20120028A1/es not_active Application Discontinuation
- 2009-11-10 US US13/129,130 patent/US8529954B2/en active Active
- 2009-11-10 DK DK09768176T patent/DK2349217T3/da active
- 2009-11-10 SM SM20190721T patent/SMT201900721T1/it unknown
- 2009-11-10 ES ES09768176T patent/ES2749803T3/es active Active
- 2009-11-10 CN CN2009801457609A patent/CN102215822A/zh active Pending
- 2009-11-10 JP JP2011543797A patent/JP2012508784A/ja active Pending
- 2009-11-10 SI SI200932005T patent/SI2349217T1/sl unknown
- 2009-11-10 WO PCT/FR2009/052169 patent/WO2010055260A1/fr not_active Ceased
- 2009-11-10 PL PL09768176T patent/PL2349217T3/pl unknown
- 2009-11-10 HU HUE09768176A patent/HUE046321T2/hu unknown
- 2009-11-10 CA CA2743767A patent/CA2743767C/fr active Active
- 2009-11-10 EA EA201100758A patent/EA023305B1/ru not_active IP Right Cessation
- 2009-11-10 UA UAA201105987A patent/UA103057C2/ru unknown
- 2009-11-10 NZ NZ592850A patent/NZ592850A/xx not_active IP Right Cessation
- 2009-11-13 TW TW098138675A patent/TWI446906B/zh active
- 2009-11-16 AR ARP090104424A patent/AR074351A1/es unknown
-
2011
- 2011-05-11 TN TN2011000231A patent/TN2011000231A1/fr unknown
- 2011-05-12 IL IL212847A patent/IL212847A/en active IP Right Grant
- 2011-05-13 CU CU20110109A patent/CU20110109A7/es unknown
- 2011-05-13 MA MA33838A patent/MA32790B1/fr unknown
- 2011-05-13 CL CL2011001114A patent/CL2011001114A1/es unknown
- 2011-05-13 ZA ZA2011/03542A patent/ZA201103542B/en unknown
- 2011-05-13 CO CO11059012A patent/CO6382106A2/es not_active Application Discontinuation
-
2019
- 2019-10-30 CY CY20191101121T patent/CY1122209T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120028A1 (es) | Nueva composicion a base de acido gamma-hidroxibutirico | |
| AR077864A1 (es) | Microgranulos flotantes | |
| AR085360A1 (es) | GRANULADOS DE ACIDO g-HIDROXIBUTIRICO | |
| PE20130063A1 (es) | Formulaciones orales y sales lipofilicas de metilnaltrexona | |
| PE20131352A1 (es) | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar | |
| PE20110893A1 (es) | Formulacion farmaceutica que contiene 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluorobencil]-2h-ftalazin-1-ona | |
| PE20060505A1 (es) | Composicion farmaceutica de metilamida del acido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluoro-fenoxi}-piridin-2-carboxilico en la forma de una dispersion solida util en trastornos hiperproliferativos | |
| PE20070693A1 (es) | Composiciones farmaceuticas solidas que contienen pregabalina | |
| PE20080153A1 (es) | Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp) | |
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| AR075028A1 (es) | Composicion farmaceutica solida que comprende amlodipina y losartan | |
| IN2012MN02923A (es) | ||
| CO6361904A2 (es) | Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo | |
| UY32441A (es) | Composicion farmaceutica, metodos de tratamiento y sus usos | |
| PE20120916A1 (es) | Nuevas formulaciones farmaceuticas contra el uso indebido de farmacos | |
| PE20181177A1 (es) | Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas | |
| CL2007002485A1 (es) | Proceso para preparar una forma de dosificacion farmaceutica oral solida de leberacion extendida que comprende un agente aactivo y oxido de polietileno de peso molecular de al menos 1.000.000, que incluye un paso de curado sometiendola a la temperatura de reblandecimiento o fusion (al menos parcial) del oxido de polietileno. | |
| PE20090951A1 (es) | Suspension pediatrica estabilizada de carisbamato | |
| PE20070698A1 (es) | Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol | |
| FR2975291B1 (fr) | Composition de decoloration des fibres keratiniques sous forme de tablette avec persulfate et un sel d'ammonium | |
| PE20141115A1 (es) | Comprimido de desintegracion oral | |
| PE20080887A1 (es) | Composiciones de carbamatos de fenilalquilo | |
| BR112012032463A2 (pt) | composição farmacêutica para administração oral. | |
| CL2013002234A1 (es) | Uso de una composicion farmaceutica que comprende al menos una prostaciclina o un analogo de la misma seleccionado entre treprostinil, ilorpost, cicaprost o beraprost, y al menos un inhibidor de fosfodiesterasa 4 (pde4), porque sirve en la prevencion o tratamiento de la fibrosis quistica. | |
| PE20081106A1 (es) | Comprimidos pediatricos de capecitabina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |